Rakeshchandra R Meka1,2, Shivaprasad H Venkatesha1,2, Bodhraj Acharya1,2, Kamal D Moudgil1,2,3. 1. Baltimore Veterans Affairs Medical Center, Baltimore, MD 21201, USA. 2. Department of Microbiology & Immunology, University of Maryland School of Medicine, Baltimore, MD 21201, USA. 3. Department of Medicine, Division of Rheumatology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Abstract
Aim: Rheumatoid arthritis is an autoimmune disease affecting the joints. Antiarthritic drugs are given systemically, thereby exposing various healthy organs to these drugs, resulting in adverse reactions. Accordingly, there is an urgent need for targeted drug delivery methods for inflamed joints. Materials & methods: We developed a liposomal drug delivery system using a novel peptide ligand (CKPFDRALC) named ART-2, which homes to the inflamed joints when injected intravenously to rats with adjuvant-induced arthritis. Results: The ART-2-coated liposomes encapsulating an antiarthritic drug, dexamethasone (DEX), were more effective in inhibiting arthritis progression than control-DEX liposomes or free DEX, despite a comparable safety profile. Conclusion: Peptide-targeted therapy has advantages over conventional drug delivery and can be adapted for rheumatoid arthritis therapy.
Aim: Rheumatoid arthritis is an autoimmune disease affecting the joints. Antiarthritic drugs are given systemically, thereby exposing various healthy organs to these drugs, resulting in adverse reactions. Accordingly, there is an urgent need for targeted drug delivery methods for inflamed joints. Materials & methods: We developed a liposomal drug delivery system using a novel peptide ligand (CKPFDRALC) named ART-2, which homes to the inflamed joints when injected intravenously to rats with adjuvant-induced arthritis. Results: The ART-2-coated liposomes encapsulating an antiarthritic drug, dexamethasone (DEX), were more effective in inhibiting arthritis progression than control-DEX liposomes or free DEX, despite a comparable safety profile. Conclusion: Peptide-targeted therapy has advantages over conventional drug delivery and can be adapted for rheumatoid arthritis therapy.
Authors: Paul E Szmitko; Chao-Hung Wang; Richard D Weisel; John R de Almeida; Todd J Anderson; Subodh Verma Journal: Circulation Date: 2003-10-21 Impact factor: 29.690
Authors: A S Vanniasinghe; N Manolios; S Schibeci; C Lakhiani; E Kamali-Sarvestani; R Sharma; V Kumar; M Moghaddam; M Ali; V Bender Journal: Clin Immunol Date: 2014-01-16 Impact factor: 3.969
Authors: Sarah E Wythe; Danielle DiCara; Taher E I Taher; Ciara M Finucane; Rita Jones; Michele Bombardieri; Y K Stella Man; Ahuva Nissim; Stephen J Mather; Yuti Chernajovsky; Costantino Pitzalis Journal: Ann Rheum Dis Date: 2012-07-27 Impact factor: 19.103
Authors: Noémi Anna Nagy; Aram M de Haas; Teunis B H Geijtenbeek; Ronald van Ree; Sander W Tas; Yvette van Kooyk; Esther C de Jong Journal: Front Immunol Date: 2021-05-13 Impact factor: 7.561
Authors: Yufei Xie; Panagiota Papadopoulou; Björn de Wit; Jan C d'Engelbronner; Patrick van Hage; Alexander Kros; Marcel J M Schaaf Journal: Cells Date: 2022-02-15 Impact factor: 6.600